Cargando…

Antiangiogenic Therapy for Diabetic Nephropathy

Angiogenesis has been shown to be a potential therapeutic target for early stages of diabetic nephropathy in a number of animal experiments. Vascular endothelial growth factor (VEGF) is the main mediator for abnormal angiogenesis in diabetic glomeruli. Although beneficial effects of anti-VEGF antibo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tanabe, Katsuyuki, Maeshima, Yohei, Sato, Yasufumi, Wada, Jun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2017
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5556994/ https://www.ncbi.nlm.nih.gov/pubmed/28835895 http://dx.doi.org/10.1155/2017/5724069

Ejemplares similares

Endogenous Antiangiogenic Factors in Chronic Kidney Disease: Potential Biomarkers of Progression
por: Tanabe, Katsuyuki, et al.
Publicado: (2018)

Deletion of pro-angiogenic factor vasohibin-2 ameliorates glomerular alterations in a mouse diabetic nephropathy model
por: Masuda, Kana, et al.
Publicado: (2018)

Vasohibin-1, a Negative Feedback Regulator of Angiogenesis, Ameliorates Renal Alterations in a Mouse Model of Diabetic Nephropathy
por: Nasu, Tatsuyo, et al.
Publicado: (2009)

Antiangiogenic therapy in diabetic nephropathy: A double-edged sword
por: Tao, Qian-Ru, et al.
Publicado: (2021)

Antiangiogenic Therapy for Patients with Recurrent and Newly Diagnosed Malignant Gliomas
por: Shirai, Katsuyuki, et al.
Publicado: (2012)

Antiangiogenic Therapy for Glioma
por: Cea, Valentina, et al.
Publicado: (2012)

Antiangiogenic Cancer Therapy
por: Maxwell, P H, et al.
Publicado: (2009)

Antiangiogenic therapy in breast cancer
por: Gampenrieder, Simon Peter, et al.
Publicado: (2017)

Antiangiogenic therapy for breast cancer
por: Nielsen, Dorte Lisbet, et al.
Publicado: (2010)

Exacerbation of Diabetic Renal Alterations in Mice Lacking Vasohibin-1
por: Hinamoto, Norikazu, et al.
Publicado: (2014)

Antiangiogenic therapies in ovarian cancer
por: Reinthaller, Alexander
Publicado: (2016)

Antiangiogenic therapy
por: Avitabile, T
Publicado: (2010)

Antiangiogenic Steroids in Human Cancer Therapy
por: Pietras, Richard J., et al.
Publicado: (2005)

Nivolumab-induced IgA nephropathy in a patient with advanced gastric cancer: A case report
por: Tanabe, Katsuyuki, et al.
Publicado: (2020)

Vasohibin‐1 deficiency enhances renal fibrosis and inflammation after unilateral ureteral obstruction
por: Watatani, Hiroyuki, et al.
Publicado: (2014)

Antiangiogenic therapy reverses the immunosuppressive breast cancer microenvironment
por: Chen, Wuzhen, et al.
Publicado: (2021)

New perspectives in glioblastoma antiangiogenic therapy
por: Popescu, Alisa Madalina, et al.
Publicado: (2015)

The inefficacy of antiangiogenic therapies
por: Ribatti, Domenico
Publicado: (2010)

Antiangiogenic therapies in urogenital malignancies: Fiction or fact?
por: Haidl, Friederike, et al.
Publicado: (2017)

Antiangiogenic gene therapy of cancer: recent developments
por: Tandle, Anita, et al.
Publicado: (2004)

Interaction between Immunotherapy and Antiangiogenic Therapy for Cancer
por: Furukawa, Koichi, et al.
Publicado: (2020)

Use of Antiangiogenic Therapies in Pediatric Solid Tumors
por: Ollauri-Ibáñez, Claudia, et al.
Publicado: (2021)

Progress on Antiangiogenic Therapy for Patients with Malignant Glioma
por: Ahluwalia, Manmeet S., et al.
Publicado: (2010)

Combining antiangiogenic therapy and radiation in nasopharyngeal carcinoma
por: Chen, Zhuo, et al.
Publicado: (2015)

Escaping Antiangiogenic Therapy: Strategies Employed by Cancer Cells
por: Pinto, Mauricio P., et al.
Publicado: (2016)

Recent Advancements of Nanomedicine towards Antiangiogenic Therapy in Cancer
por: Mukherjee, Anubhab, et al.
Publicado: (2020)

Genetic Deletion of Vasohibin-2 Exacerbates Ischemia-Reperfusion-Induced Acute Kidney Injury
por: Miyake, Hiromasa, et al.
Publicado: (2020)

Antiangiogenic Therapy and Mechanisms of Tumor Resistance in Malignant Glioma
por: Rahman, Ruman, et al.
Publicado: (2010)

TGF-β Superfamily Receptors—Targets for Antiangiogenic Therapy?
por: Otten, Jasmin, et al.
Publicado: (2010)

Antiangiogenic Effects of VH02, a Novel Urea Derivative: In Vitro and in Vivo Studies
por: Phowichit, Suwadee, et al.
Publicado: (2016)

Antiangiogenic Effect of Alkaloids
por: Alasvand, Masoud, et al.
Publicado: (2019)

Safety profiles of current antiangiogenic therapies for metastatic colorectal cancer
por: Fuloria, Jyotsna
Publicado: (2012)

Challenges of antiangiogenic cancer therapy: trials and errors, and renewed hope
por: Medina, Miguel Ángel, et al.
Publicado: (2007)

Urinary and Plasma Levels of Vasohibin-1 Can Predict Renal Functional Deterioration in Patients with Renal Disorders
por: Hinamoto, Norikazu, et al.
Publicado: (2014)

Sunitinib: the antiangiogenic effects and beyond
por: Hao, Zhonglin, et al.
Publicado: (2016)

Acquired tumor resistance to antiangiogenic therapy: Mechanisms at a glance
por: Zarrin, Bahare, et al.
Publicado: (2017)

Antiangiogenic cytokines as potential new therapeutic targets for resveratrol in diabetic retinopathy
por: Popescu, Mihaela, et al.
Publicado: (2018)

Novel concepts of antiangiogenic therapies in metastatic renal cell cancer
por: Pichler, Renate, et al.
Publicado: (2017)

Relationship between hypoxia and response to antiangiogenic therapy in metastatic colorectal cancer
por: Ulivi, Paola, et al.
Publicado: (2016)

Recent Advances and Impact of Chemotherapeutic and Antiangiogenic Nanoformulations for Combination Cancer Therapy
por: Rajora, Amit Kumar, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_fmt3hhk3d2ppmebippg7ito8vq